Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects

NCT02439359 is registered in ClinicalTrials.gov with ContraFect as lead sponsor.

NCT NCT02439359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02439359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects
Lead sponsor
ContraFect
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2015
Completion date
December 31, 2015
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

staphylococcus aureus bloodstream infections (bsi; bacteremia)